One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the impact of Ziprasidone HCl on the distribution of
metabolic syndrome (MS) risk factors in a population of Bipolar patients presenting with
glucose intolerance, dyslipidemia and/or elevated waist circumference associated with their
current antipsychotic medication.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.